|
クラモチ ヒデカズ
KURAMOCHI HIDEKAZU
倉持 英和 所属 医学部 医学科（東京女子医科大学病院） 職種 准教授 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読なし |
| 表題 | Long-term Results of a Phase II Study of Neoadjuvant SOX for Advanced Gastric Cancer |
| 掲載誌名 | 正式名：Anticancer research 略 称：Anticancer Res ISSNコード：17917530/02507005 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 44(1),pp.195-204 |
| 著者・共著者 | ITO Shunichi†, KURAMOCHI HIDEKAZU*, SERIZAWA Akiko, OTA Masaho, KATAGIRI SATOSHI, MAEDA Shinsuke, HOSODA Kei |
| 担当区分 | 2nd著者,責任著者 |
| 発行年月 | 2024/01 |
| 概要 | BACKGROUND/AIM:This study aimed to evaluate the long-term survival outcomes from our previous study: a phase II study of neoadjuvant chemotherapy with S-1 plus oxaliplatin for cT4 or N2-3 advanced gastric cancer.PATIENTS AND METHODS:The patients with clinical T4 and/or N2 or more lymph nodes received two cycles (3 weeks per cycle) of neoadjuvant chemotherapy with S-1 plus oxaliplatin (oxaliplatin at 130 mg/m2 on day 1 and S-1 at 80-120 mg/day on days 1 to 14), followed by gastrectomy with D2 lymphadenectomy. The final preplanned analysis of long-term outcomes, including overall and relapse-free survival, was performed. This trial has been completed and registered with the University Hospital Medical Information Network Clinical Trials Registry under number UMIN 000024656.RESULTS:Between May 2016 and March 2019, 30 patients were enrolled. All patients completed the protocol. After a median follow-up of 50 months for surviving patients, the 3-year overall and recurrence-free survival rates were 80.0% and 76.7%, respectively, at the last follow-up in March 2023, whereas the 5-year overall and recurrence-free survival rates were 72.7% and 73.0%, respectively.CONCLUSION:The administration of two cycles of neoadjuvant chemotherapy with S-1 plus oxaliplatin, followed by D2 gastrectomy, was associated with relatively good long-term oncologic outcomes for patients with high-risk gastric cancer. |
| DOI | 10.21873/anticanres.16802 |
| PMID | 38160004 |